Literature DB >> 6309009

Effects of beta-blockade on glycogen metabolism in human subjects during exercise.

D Chasiotis, R Brandt, R C Harris, E Hultman.   

Abstract

The effect of beta-blockade on glycogen metabolism during isometric and dynamic exercise in humans has been investigated. Isometric exercise increased the glycogenolytic rate in muscle but had no effect on the cAMP content. Neither the metabolic pattern nor the time of contraction was affected by beta-blockade. Dynamic exercise increased the cAMP content in muscle by about 100%. The cAMP content at rest was significantly reduced after propranolol infusion and did not increase during exercise. Total hexosemonophosphates increased sixfold during exercise but little or no increase occurred after administration of propranolol. The accumulation of lactate in muscle was slightly reduced during exercise following beta-blockade. The fraction of phosphorylase in the alpha form was 22.5% of the total at rest but decreased to 16% at exhaustion. Synthetase I was similarly decreased. During exercise with propranolol phosphorylase alpha decreased further to 3%, whereas synthetase I was unchanged. It is concluded that beta-blockade has no effect on muscle glycogenolysis during isometric contraction but decreases the rate of glycogen degradation during dynamic exercise at high work loads due to changes in the phosphorylase-synthetase system.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6309009     DOI: 10.1152/ajpendo.1983.245.2.E166

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  13 in total

Review 1.  Exercise metabolism and beta-blocker therapy. An update.

Authors:  A Head
Journal:  Sports Med       Date:  1999-02       Impact factor: 11.136

2.  Effect of beta-adrenergic blockade on plasma lactate concentration during exercise at high altitude.

Authors:  A J Young; P M Young; R E McCullough; L G Moore; A Cymerman; J T Reeves
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1991

3.  Beta(2)-Adrenergic activation increases glycogen synthesis in L6 skeletal muscle cells through a signalling pathway independent of cyclic AMP.

Authors:  D L Yamamoto; D S Hutchinson; T Bengtsson
Journal:  Diabetologia       Date:  2006-11-22       Impact factor: 10.122

4.  A comparison of the effects of the selective peripheral alpha 1-blocker terazosin with the selective beta 1-blocker atenolol on blood pressure, exercise performance and the lipid profile in mild-to-moderate essential hypertension.

Authors:  M Ligueros; R Unwin; M R Wilkins; J Humphreys; S J Coles; J Cleland
Journal:  Clin Auton Res       Date:  1992-12       Impact factor: 4.435

5.  Contraction-mediated inactivation of glycogen synthase is accompanied by inactivation of glycogen synthase phosphatase in human skeletal muscle.

Authors:  Y Kida; A Katz; A D Lee; D M Mott
Journal:  Biochem J       Date:  1989-05-01       Impact factor: 3.857

Review 6.  The use of ratings of perceived exertion for exercise prescription in patients receiving beta-blocker therapy.

Authors:  R Eston; D Connolly
Journal:  Sports Med       Date:  1996-03       Impact factor: 11.136

Review 7.  Beta-adrenoceptor blockade and exercise. An update.

Authors:  M A Van Baak
Journal:  Sports Med       Date:  1988-04       Impact factor: 11.136

Review 8.  Exercise performance and beta-blockade.

Authors:  P A Tesch
Journal:  Sports Med       Date:  1985 Nov-Dec       Impact factor: 11.136

9.  Effects of short-term dietary change from high fat to high carbohydrate diets on the storage and utilization of glycogen and triacylglycerol in untrained rats.

Authors:  S Saitoh; T Matsuo; K Tagami; H Chang; K Tokuyama; M Suzuki
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1996

10.  Exercise-induced alterations in extracellular signal-regulated kinase 1/2 and mammalian target of rapamycin (mTOR) signalling to regulatory mechanisms of mRNA translation in mouse muscle.

Authors:  David L Williamson; Neil Kubica; Scot R Kimball; Leonard S Jefferson
Journal:  J Physiol       Date:  2006-03-16       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.